Allakos Inc. ALLK
Set alert
At close · May 15
52-week range unavailable
- YTD
- -72.80%
- 1 year
- -72.34%
- Open
- 0.3291
- Prev close
- 0.3291
- Mkt cap
- 113.47M
- Vol
- 1.31M
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 0.3291
- High
- 0.3291
- Forward P/E
- -2.02
- Beta
- 1.02
- Short ratio
- 1.78
- Inst. own
- 81.58%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Aug 7, 2024
- 50-d avg
- 1.10
- 200-d avg
- 1.00
- 1y target
- 3.35
News
1 year ago prnewswire.com
$HAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Allakos Inc. - ALLK
NEW YORK , April 2, 2025 /PRNewswire/ -- Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2024…
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Wednesday's Intraday Session
12 Health Care Stocks Moving In Wednesday's Intraday Session
1 year ago businesswire.com
ALLK Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Allakos Inc. Is Fair to Shareholders
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Allakos Inc. (NASDAQ: ALLK) to Concentra Biosciences, LLC for $0.33 in cash per share is…
1 year ago businesswire.com
Shareholder Alert: The Ademi Firm Investigates Whether Allakos Inc. Is Obtaining a Fair Price for Its Public Shareholders
MILWAUKEE--(BUSINESS WIRE)--The Ademi Firm is investigating Allakos (Nasdaq: ALLK) for possible breaches of fiduciary duty and other violations of law in its transaction with Concentra. Click here to…
1 year ago globenewswire.com
Allakos Inc. Enters into Agreement to Be Acquired by Concentra Biosciences, LLC for $0.33 in Cash per Share
SAN CARLOS, Calif., April 02, 2025 (GLOBE NEWSWIRE) -- Allakos Inc. (“Allakos”) (Nasdaq: ALLK), a biotechnology company that has been developing antibodies for the treatment of allergic, inflammatory…
1 year ago globenewswire.com
Allakos Provides Business Update and Reports Fourth Quarter 2024 Financial Results
SAN CARLOS, Calif., March 12, 2025 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company that has been developing antibodies for the treatment of allergic,…
1 year ago globenewswire.com
Lycia Therapeutics Announces the Appointment of Chin Lee, MD, MPH, as Chief Medical Officer and Reveals Immunology Pipeline
SOUTH SAN FRANCISCO, Calif., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Lycia Therapeutics, Inc., a biotechnology company developing lysosomal targeting chimera (LYTAC)-based protein degradation therapies to…
1 year ago globenewswire.com
Kuehn Law Encourages Investors of Allakos Inc. to Contact Law Firm
NEW YORK, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Allakos Inc. (NASDAQ: ALLK) breached their…
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Monday's Pre-Market Session
12 Health Care Stocks Moving In Monday's Pre-Market Session
1 year ago benzinga.com
Why Is Allakos Stock Plunging On Monday?
On Monday, Allakos Inc (NASDAQ: ALLK) revealed topline results from its phase 1 clinical trial of AK006 in chronic spontaneous urticaria (CSU), a skin disorder.
1 year ago globenewswire.com
Allakos Announces Topline Results from its Phase 1 Trial of AK006 in Patients with Chronic Spontaneous Urticaria and Announces Restructuring
– AK006 did not demonstrate therapeutic activity in CSU –– Allakos will discontinue further development of AK006, reduce workforce by 75% and explore strategic alternatives –– Management to host…
1 year ago prnewswire.com
Kuehn Law Encourages Investors of Allakos Inc. to Contact Law Firm
NEW YORK , Dec. 19, 2024 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Allakos Inc. (NASDAQ: ALLK) breached their…
1 year ago zacks.com
All You Need to Know About Allakos (ALLK) Rating Upgrade to Buy
Allakos (ALLK) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
1 year ago seekingalpha.com
Allakos Runs Up Into A Near-Term Catalyst
Allakos shifted focus to AK006 in 2024 after lirentelimab's failure in phase 2 trials for atopic dermatitis and chronic spontaneous urticaria. Phase 1 work with intravenous and subcutaneous AK006…
1 year ago globenewswire.com
Allakos Provides Business Update and Reports Third Quarter 2024 Financial Results
SAN CARLOS, Calif., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing antibodies for the treatment of allergic, inflammatory and…
-
2 years ago benzinga.com
12 Health Care Stocks Moving In Wednesday's After-Market Session
12 Health Care Stocks Moving In Wednesday's After-Market Session
2 years ago globenewswire.com
Allakos Announces Phase 1 Trial Results of Subcutaneous AK006 in Healthy Volunteers
– Subcutaneously administered AK006 showed approximately 77% bioavailability and prolonged receptor occupancy on mast cells –– Subcutaneous AK006 was well-tolerated with a favorable safety profile ––…
2 years ago globenewswire.com
Allakos Provides Business Update and Reports Second Quarter 2024 Financial Results
SAN CARLOS, Calif., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing antibodies for the treatment of allergic, inflammatory and…
2 years ago accesswire.com
The Schall Law Firm Initiates Investigation Into Allegations Against Allakos Inc And Encourages Impacted Investors To Engage
LOS ANGELES, CA / ACCESSWIRE / June 26, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Allakos Inc.…
2 years ago globenewswire.com
Allakos Announces Positive Results from its Ongoing Phase 1 Trial of AK006 in Healthy Volunteers, with AK006 Demonstrating High Receptor Occupancy on Mast Cells and a Favorable Safety Profile
– AK006 achieved serum concentrations consistent with levels demonstrating inhibitory activity in preclinical experiments –– Skin biopsies from subjects treated with AK006 show high receptor…
2 years ago accesswire.com
The Schall Law Firm Begins Probe Into Claims Against Allakos Inc And Urges Affected Investors To Participate
LOS ANGELES, CA / ACCESSWIRE / June 25, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Allakos Inc.…
2 years ago accesswire.com
The Schall Law Firm Initiates Investigation Into Allegations Against Allakos Inc And Encourages Impacted Investors To Join
LOS ANGELES, CA / ACCESSWIRE / June 24, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Allakos Inc.…
2 years ago accesswire.com
The Schall Law Firm Starts Probe Into Claims Against Allakos Inc And Urges Affected Investors To Participate
LOS ANGELES, CA / ACCESSWIRE / June 23, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Allakos Inc.…
-
3 years ago benzinga.com
Stocks That Hit 52-Week Lows On Tuesday
On Tuesday, 647 companies set new 52-week lows.
-
3 years ago benzinga.com
Stocks That Hit 52-Week Lows On Thursday
During the session on Thursday, 461 stocks hit new 52-week lows.
-
3 years ago benzinga.com
Stocks That Hit 52-Week Lows On Monday
Monday's session saw 175 companies set new 52-week lows.
-
3 years ago benzinga.com
Stocks That Hit 52-Week Lows On Thursday
On Thursday, 283 companies set new 52-week lows.
-
3 years ago benzinga.com
Stocks That Hit 52-Week Lows On Tuesday
On Tuesday, 210 companies reached new 52-week lows.
-
3 years ago benzinga.com
Benzinga's Top Ratings Upgrades, Downgrades For May 12, 2023
Benzinga's Top Ratings Upgrades, Downgrades For May 12, 2023
-
3 years ago benzinga.com
Why Rivian Automotive Shares Are Trading Lower By Over 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Gainers Virax Biolabs Group Limited (NASDAQ: VRAX) jumped 99% to $1.3195 after the company announced an agreement for the distribution of an Avian Influenza A Virus real-time PCR test kit to the…
-
3 years ago benzinga.com
Benzinga's Top Ratings Upgrades, Downgrades For March 7, 2023
Benzinga's Top Ratings Upgrades, Downgrades For March 7, 2023
-
3 years ago benzinga.com
Why Party City Holdco Shares Tumbled Over 40%; Here Are 98 Biggest Movers From Yesterday
Gainers Unique Fabricating, Inc. (NYSE: UFAB) jumped 56.3% to close at $0.8205 on Tuesday. Unique Fabricating posted a Q3 loss of $0.90 per share after the closing bell on Tuesday.
-
4 years ago benzinga.com
Why Aridis Pharmaceuticals Shares Plunged Around 30%; Here Are 81 Biggest Movers From Yesterday
Gainers
-
4 years ago benzinga.com
Why LAVA Therapeutics Shares Are Trading Higher By 97%, Here Are 49 Stocks Moving In Monday's Mid-Day Session
Gainers
-
4 years ago benzinga.com
Why Nuwellis Surged Over 121%; Here Are 66 Biggest Movers From Yesterday
Gainers
-
4 years ago benzinga.com
Why Baker Hughes Shares Dropped 8%; Here Are 64 Biggest Movers From Yesterday
Gainers Pagaya Technologies Ltd. (NASDAQ: PGY) shares climbed 129.6% to close at $6.20 on Wednesday. Pagaya Technologies is expected to announce its Q2 earnings on August 16, 2022.
-
4 years ago benzinga.com
89 Biggest Movers From Friday
Gainers Revlon, Inc. (NYSE: REV) jumped 91.3% to close at $3.73 on Friday after the company filed for Chapter 11 bankruptcy.
-
4 years ago benzinga.com
Stocks That Hit 52-Week Lows On Wednesday
On Wednesday, 215 companies set new 52-week lows.
-
4 years ago benzinga.com
Stocks That Hit 52-Week Lows On Tuesday
On Tuesday, 540 companies set new 52-week lows.
-
4 years ago benzinga.com
Stocks That Hit 52-Week Lows On Wednesday
During Wednesday's trading, 435 companies set new 52-week lows.
-
4 years ago benzinga.com
Stocks That Hit 52-Week Lows On Thursday
During Thursday, 849 stocks hit new 52-week lows.
-
4 years ago benzinga.com
Stocks That Hit 52-Week Lows On Wednesday
Wednesday's session saw 784 companies set new 52-week lows.
-
4 years ago benzinga.com
Stocks That Hit 52-Week Lows On Tuesday
During Tuesday, 581 stocks hit new 52-week lows. Interesting Highlights From Today's 52-Week Lows Meta Platforms (NASDAQ:FB) was the biggest company on a market cap basis to set a new 52-week low.
-
4 years ago benzinga.com
Stocks That Hit 52-Week Lows On Friday
On Friday, 431 companies hit new 52-week lows.
-
4 years ago benzinga.com
Stocks That Hit 52-Week Lows On Thursday
On Thursday, 236 companies hit new 52-week lows.
-
4 years ago benzinga.com
Stocks That Hit 52-Week Lows On Wednesday
On Wednesday, 160 companies hit new 52-week lows.
-
4 years ago benzinga.com
Stocks That Hit 52-Week Lows On Tuesday
On Tuesday, 242 companies hit new 52-week lows.
-
4 years ago benzinga.com
Stocks That Hit 52-Week Lows On Tuesday
Tuesday's session saw 729 companies set new 52-week lows.
-
4 years ago benzinga.com
Stocks That Hit 52-Week Lows On Tuesday
During Tuesday's trading, 505 companies set new 52-week lows.
-
4 years ago benzinga.com
Stocks That Hit 52-Week Lows On Friday
On Friday, 313 companies hit new 52-week lows.